Downregulating oncogenic receptor: From bench to clinic

Zhu, George; Saboor-Yaraghi, Ali-Akmbar; Yarden, Yosef; Santos, Joana; Jc, Neil

doi:10.15761/hmo.1000106

Cited by 14 publications

(14 citation statements)

References 175 publications

(204 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In literature reports, another toxicological test was applied 6g (200µg EGF/g) rhEGF gelatin to the skin wound for 36 days on the back of a rabbit, 20 times its clinical dose, no adverse side effects regarding the local skin and organ toxicity was observed (data not shown). Moreover, in vivo over expression of epidermal growth factor in transgenic mice could lead to growth retardation, but no tumor was observed in transgenic animals [42][43][44][45][46][47][48] . In current study realized that in preparation of rhEGF medicine based on the earlier experiments of an oncogenic pml/retinoic acid receptor alpha fusion (retinoid pharmacology) in APL and an aberrant androgen receptor with its methyltestosterone drug in the induction of breast tumors 29,30 and subsequentially the earliest discovery of normal or proto-oncogenic receptor kinase EGF receptor in cell proliferative signaling in wound healing, and in June,1991 patent application for rhEGF powder and its specific Shampo liquid, and its newly Band-Aids.…”

Section: Figure 4: Observations In Different Ratsmentioning

confidence: 99%

Enhancement of Wound Healing by Topical Application of Epidermal Growth Factor in Animal Model

Zhu

Xp³

et al. 2020

Univ J Pharm Res

Self Cite

View full text Add to dashboard Cite

Objective: Wound healing is a complex process of biological events involving re-epithelialization and granulation that are mainly mediated by several endogenously released growth factors such as epidermal growth factor. This work was undertaken to study the effects of various doses of locally applied recombinant human epidermal growth factor (rhEGF) on wound healing in rats. Methods: Recombinant human EGF consists of 53 amino acids. In vitro, rhEGF promoted it’s obvious cell growth and proliferation when added to cultured 3T3 cells using MTT assay. In the test groups, in vivo, wound sites were given daily with a solution containing 2, 5, 10, 50ug of EGF spray and 40ug of EGF ointment, respectively. We presented evidence that a significant decreased healing time in wound was observed in all rhEGF groups when compared with the control, and reach to its maximal efficacy at 10ug/ml of rhEGF spray. Results: The rate of wound closure was over 50 per cent at initial 3 days of treatment. Treatment with rhEGF significantly decreased the length of time to over 50 per cent healing by approximately 4-5 days, and that to 70 per cent and 90 per cent healing by approximately 3-4 days and 3 days, respectively. A stimulatory, dose-dependent effect of EGF on wound healing was observed with increased hEGF concentration. In toxicological group, higher doses of 100ug/ml of rhEGF spray was applied by local dorsal incision in rats. Moreover, a dose of single 200ug, single 300ug or 300ug within 24 hours of subcutaneous and intramuscular rhEGF injection was given respectively. There were no significant adverse side effects.Conclusion: Current study recommended a proposal of clinical drug doses in wound at 2µg, 5 µg and 10 µg /ml of rhEGF spray, and 10 µg and even higher 40 µg rhEGF/g of ointment. The results indicated that prepared rhEGF by our genetic engineering is safe, and is emerging in clinical effective use in assisting wound healing time. Peer Review History: Received 8 January 2020; Revised 12 February; Accepted 2 March, Available online 15 March 2020 UJPR follows the most transparent and toughest ‘Advanced OPEN peer review’ system. The identity of the authors and, reviewers will be known to each other. This transparent process will help to eradicate any possible malicious/purposeful interference by any person (publishing staff, reviewer, editor, author, etc) during peer review. As a result of this unique system, all reviewers will get their due recognition and respect, once their names are published in the papers. We expect that, by publishing peer review reports with published papers, will be helpful to many authors for drafting their article according to the specifications. Auhors will remove any error of their article and they will improve their article(s) according to the previous reports displayed with published article(s). The main purpose of it is ‘to improve the quality of a candidate manuscript’. Our reviewers check the ‘strength and weakness of a manuscript honestly’. There will increase in the perfection, and transparency. Received file Average Peer review marks at initial stage: 6.5/10 Average Peer review marks at publication stage: 8.5/10 Reviewer(s) detail: Name: Asmaa Ahmed Mohamed Ahmed Khalifa Affiliation: Pharos University, Alexandria, Egypt E-mail: asmaa.khalifa@pua.edu.eg Name: Dr. Sabah Hussien El-Ghaiesh Affiliation: Tanta University, Egypt E-mail: s.ghaiesh@gmail.com Comments of reviewer(s): Similar Articles: POTENTIAL OF SNAKEHEAD FISH (OPHIOCEPHALUS STRIATUS) IN ACCELERATING WOUND HEALING

show abstract

Section: Figure 4: Observations In Different Ratsmentioning

confidence: 99%

Enhancement of Wound Healing by Topical Application of Epidermal Growth Factor in Animal Model

Zhu

Xp³

et al. 2020

Univ J Pharm Res

Self Cite

View full text Add to dashboard Cite

show abstract

“…Oncogenic receptor AR variants（Pca) [24][25] ; ER pro-neoplastic signaling [26][27] , neoplastic ESR1-CCDC170 fusion(also oncogenic receptor ERalpha fusion)（breast cancer) 7,28 ;GRβ aberrant signaling（Cushing's disease,erythrocytosis, GR + breast cancer, Nelson's syndrome) [29][30][31] ; FSH/FSH receptor oncogenic signaling（preneoplastic ovarian surface epithelial cells)…”

Section: Steroid Receptorsmentioning

confidence: 99%

“…Because It is no need to targeting receptors in normal condition, actually, targeting therapy now is shift mainly toward oncogenic receptors in tumours in tumor hospitals, even if we won't citing in literature 7 . EpCAM molecule a novel oncogenic receptor is shift toward new member family and targeting its antibodies 34 .…”

Section: Introductionmentioning

confidence: 99%

EpCAM- AN OLD CANCER ANTIGEN, TURNED ONCOGENIC RECEPTOR AND ITS TAGETING IMMUNOTHERAPY

Zhu

2018

UJPR

Self Cite

View full text Add to dashboard Cite

EpCAM is a cell adhesion molecule. Its structure, its expression and the oncogenic potential, and its signaling network and target therapy were in concise reviewed. In recent advances,in addition to PI3K/akt and Raf/MAPK pathway involving in cell survival,anti-apoptosis and proliferation,and malignant initiation and progression(see figure by Zhu,1986-91), three distinct pathway are illustrated: EpCAM/E-cadherin-catenin-actin cytoskeleton, EpCAM/ wint-catenin signaling and its major EpCAM/ nuclear signaling presented by Munz M in 2004. Moreover, more accumulated data are needed in detail mechanism. The data may provide its cancer biology and clinical targeting therapy benefits.

show abstract

“…More others, CLIC1 was identified as a novel dominant pro-oncogenic receptor from proteomic profiling of pleomorphic human sarcoma [130]. Thus, an extensive study of thyroid hormone receptor (THR) mutations in oncogenic signaling, TSH/TSHR in thyroid disease and thyroid cancer, and also its target therapy [131][132][133], is further perspective. …”

Section: Dietary Iodine Intake and The Prevalence Of Papillary Carcinmentioning

confidence: 99%

Dietary iodine intake, thyroid diseases and the prevalence of papillary carcinoma (PTC)

Zhu¹

2018

Hematol Med Oncol

Self Cite

View full text Add to dashboard Cite

Iodine is a trace element that is essential for the synthesis of thyroid hormone. Both chronic iodine deficiency or iodine excess have been associated with hypertrophy and hyperplasia of follicular cells and the influence of thyroid hormone (T3,T4) and thyrotropin (TSH)secretion. Increase rates of the thyroid cancer are increasing after radiation exposure to 131I in children or aldolescents. In respectively, dietary iodine excess goiter, iodine induced hyperthyroidism (IIH)and IIT, Iodine intake and the prevalence of papillary carcinoma (PTC),as well as the case-control and cohort studies of thyroid cancer and intake of seafood and milk products, were reviewed. Moreover, available evidence of oncogenic thyroid hormone receptor mutants from animal experiments and clinical investigation have been a shift toward the oncogenic function of human thyroid carcinoma, and also its target therapy.

show abstract

Downregulating oncogenic receptor: From bench to clinic

Cited by 14 publications

References 175 publications

Enhancement of Wound Healing by Topical Application of Epidermal Growth Factor in Animal Model

Enhancement of Wound Healing by Topical Application of Epidermal Growth Factor in Animal Model

EpCAM- AN OLD CANCER ANTIGEN, TURNED ONCOGENIC RECEPTOR AND ITS TAGETING IMMUNOTHERAPY

Dietary iodine intake, thyroid diseases and the prevalence of papillary carcinoma (PTC)

Contact Info

Product

Resources

About